Welcome to our dedicated page for Ir-Med news (Ticker: IRME), a resource for investors and traders seeking the latest updates and insights on Ir-Med stock.
IR-MED Inc. develops non-invasive, AI-powered infrared spectrographic medical-device technology for clinical decision support. Company news centers on its platform for assessing tissue, skin and blood-related biomarkers beneath the surface, with recurring updates on PressureSafe™ for pressure injury assessment and DiaSafe™ for diabetic foot ulcer assessment.
Coverage also includes clinical studies and presentations, collaborations with healthcare institutions, grants supporting product development, shareholder updates, financing needs, intellectual-property references and leadership or governance changes. PressureSafe™ is described by the company as a handheld, skin-color-agnostic decision support device for assessing pressure injuries before visible skin breakdown.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
IR-MED (OTCQB:IRME) is set to present its innovative PressureSafe device at the NPIAP 2023 Annual Conference on March 17-18 in San Diego. This technology aims to enhance pressure injury detection, particularly among minority populations who face significant challenges. With nearly $26.8 billion spent annually on pressure injury prevention and treatment, early detection is crucial, especially for individuals with dark skin tones who suffer from these injuries at over double the rate of their lighter-skinned counterparts. The PressureSafe device utilizes infrared light and AI to provide personalized clinical feedback. The device is not yet commercially available but is expected to launch in H2 2023, pending regulatory approvals.
IR-MED has announced a partnership with Rabin Medical Center to expand usability studies for its PressureSafe device, aimed at improving the early detection of pressure injuries (PI) in patients. This device utilizes Infrared light spectroscopy and AI, demonstrating potential for significant health benefits, especially for individuals with darker skin tones who are at higher risk for PIs. The collaboration with RMC, a prominent hospital known for its research and accreditation, will enhance the study's scope and credibility. The company emphasizes the potential economic impact of PIs, with U.S. costs exceeding $26.8 billion annually.
IR-MED (OTC-PINK:IRME) has achieved significant advancements in 2022 and is preparing for a U.S. market launch in 2023. The company has completed its PressureSafe device, designed for early detection of pressure injuries, aiming to improve healthcare outcomes and reduce costs. An exclusive distribution agreement with PI Prevention Care LLC will enhance market penetration. Additionally, IR-MED is developing Nobiotics, a handheld device for diagnosing ear infections. The company raised $3.6M in late 2022, enhancing its financial position, and plans to seek FDA approval for PressureSafe in the latter half of 2023.
IR-MED (OTCQB:IRME) announced the appointment of Dr. David Dalton to its Advisory Board. Dr. Dalton, a prominent figure in healthcare with a track record of founding over 40 companies, will contribute insights on the PressureSafe device, aimed at early detection of pressure injuries (PI). His expertise is particularly relevant for enhancing care in Hispanic and African American populations, who are at a higher risk for PIs. Dr. Dalton's experience includes leadership roles in significant pharmaceutical organizations and a focus on minority health initiatives, further aligning with IR-MED's mission.
IR-MED (OTCQB: IRME) has announced a new agreement with Bina Industrial Design Ltd for the commercial design of its PressureSafe device, aimed at detecting early-stage pressure injuries. This partnership will utilize feedback from a usability study currently in progress in Israel to enhance the device's design. PressureSafe employs advanced spectrographic analysis and AI to identify conditions that may lead to pressure injuries, a significant concern in healthcare, with 60,000 related fatalities annually in the US.
IR-MED (OTCQB: IRME), a medical device innovator, has submitted a provisional patent application for its PressureSafe device, which aims to detect early-stage pressure injuries (PIs) using advanced infrared spectroscopy and AI. This development is crucial as PIs pose significant health risks, with around 60,000 related mortalities in the US annually and costs exceeding $26.8 billion. The PressureSafe device is set for usability studies in Israel, offering timely intervention data that could drastically improve patient outcomes and reduce hospital-related penalties for untreated PIs.